2021
Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis
Iliopoulou VN, Charkoftaki G, Cooper JC, Dokoumetzidis A, Joy MS. Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis. Journal Of Pharmacy And Pharmacology 2021, 73: 1683-1692. PMID: 34480477, DOI: 10.1093/jpp/rgab135.Peer-Reviewed Original ResearchConceptsPopulation pharmacokinetic modelPharmacokinetic modelAutoimmune glomerulonephritisCentral volumeSimultaneous population pharmacokinetic modelInitiation of therapyVisual predictive checkProportional error modelElimination rate constantDose regimensPopulation pharmacokineticsTotal clearancePatient variablesPlasma concentrationsCyclophosphamidePharmacokinetic evaluationPharmacokinetic parametersPatientsPlasma samplingPotential covariatesGlomerulonephritisSignificant covariatesPredictive checksFinal modelCovariates
2016
ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS
Sanai N, Li J, Boerner J, Dhruv H, Berens M, LoRusso P. ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.009.Peer-Reviewed Original ResearchPhase 0 trialsInterindividual variabilityGlioblastoma patientsPhase II studyApparent oral clearanceGlomerular filtration ratePhase I trialCL/F.CL/FSparse blood samplingElimination rate constantAbsorption rate constantPD endpointsAdult patientsII studyOral clearanceI trialSingle doseDrug exposureFiltration ratePreclinical modelsPreclinical studiesGlioma patientsPlasma ratioBlood sampling
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply